Alper Yasar

Dr. Alper Yasar

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2024 in Medicina
Verified
Journal Article
Open access
PDF file
SYSEDAT YILDIRIM
SEDAT YILDIRIM
ÖAÖzkan Alan
Özkan Alan
ZYZeynep Yüksel Yaşar
Zeynep Yüksel Yaşar
TKTugba Kaya
Tugba Kaya
GAGoncagül Akdağ
Goncagül Akdağ
NTNedim Turan
Nedim Turan
Background and Objectives: Lung cancer is the leading cause of cancer-related deaths. Spread through air spaces (STAS) is an adverse prognostic factor that has become increasingly known in recent years. This study aims to investigate the impact of STAS presence on overall survival (OS) and disease-free survival (DFS) in patients with surgically resected stage IA-IIIA lung cancer and to identify clinicopathological features associated with STAS. Materials and Methods: This research involved 311 lung cancer surgery patients. The relationship between the presence of STAS in the patients’ surgical pathology and OS and DFS values was examined. Clinicopathological features associated with the presence of STAS were determined. Results: There were 103 (33%) STAS-positive patients. Adenocarcinoma histological subtype, perineural invasion (PNI), and lymphovascular invasion (LVI) were significantly correlated with being STAS positive. STAS significantly predicted DFS and OS. One-year and five-year DFS rates were significantly lower in the STAS-positive group compared to the STAS-negative group (65% vs. 88%, 29% vs. 62%, respectively, p ≤ 0.001). Similarly, one-year and five-year OS rates were significantly lower in the STAS-positive group compared to the STAS-negative group (92% vs. 94%, 54% vs. 88%, respectively, p ≤ 0.001). In multivariate analysis, STAS was found to be an independent prognostic factor for both DFS and OS (HR: 3.2 (95%CI: 2.1–4.8) and 3.1 (95%CI: 1.7–5.5), p < 0.001 and <0.001, respectively). Conclusions: In our study, STAS was found to be an independent prognostic biomarker in operated stage IA-IIIA lung cancer patients. It may be a beneficial pathological biomarker in predicting the survival of patients and managing their treatments.

9 October 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
İBİbrahim Vedat Bayoğlu
İbrahim Vedat Bayoğlu
JHJavid Hüseynov
Javid Hüseynov
ATAlper Topal
Alper Topal
NSnadiye sever
nadiye sever
NANargiz Majidova Altuntash
Nargiz Majidova Altuntash
İÇİrfan Çiçin
İrfan Çiçin
Introduction: This study aimed to assess the role of the adjusted PNI-IMDC risk scoring system in stratifying the intermediate group of metastatic RCC patients who received TKIS in the first-line setting. Methods: A total of 185 patients were included. The adjusted PNI and IMDC model was used to divide the intermediate group into two groups: intermediate PNI-high and intermediate PNI-low groups. The statistical data were analyzed using Kaplan–Meier and Cox regression analysis. Results: The results showed that the adjusted PNI-IMDC risk score, classic IMDC, and PNI had similar prognostic values. Adjusted PNI-IMDC risk score might be used for a more homogeneous differentiation of the classic intermediate group. On the other hand, multivariate analysis revealed that the presence of nephrectomy, adjusted favorable/intermediate (PNI-high) group, ECOG performance score, and presence of bone metastasis were independent predictors of OS. Conclusions: Pre-treatment PNI, as a valuable and potential add-on biomarker to the adjusted PNI-IMDC classification model, can be helpful for establishing an improved prognostic model for intermediate group mRCC patients treated with first-line TKISs. Further validation studies are needed to clarify these findings.

30 June 2025 in TURKISH JOURNAL of CLINICS and LABORATORY
Verified
Journal Article
Open access
PDF file
SKSeda Kahraman
Seda Kahraman
MHMutlu Hızal
Mutlu Hızal
ÖGÖzge Gümüşay
Özge Gümüşay
GBGül Başaran
Gül Başaran
MSMustafa Seyyar
Mustafa Seyyar
MSMehmet Ali Nahit SENDUR
Mehmet Ali Nahit SENDUR
Aim: Hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative breast cancer which represents the most common subgroup of metastatic breast cancer (MBC). Recently, further subclassification for HER2-negative tumors has emerged as HER2-low. There is limited knowledge regarding the effect of HER2-low expression on outcomes of patients with HR-positive and HER2-negative MBC treated with CDK 4/6 inhibitors plus hormonal therapy. Therefore, we evaluated survival parameters according to HER2-low status for this patient group in this study. Material and Methods: As the Turkish Oncology Group (TOG) Project, retrospectively collected data from 423 patients with HR-positive/HER2-negative MBC treated with ribociclib and palbociclib plus letrozole therapy was assessed. Included patients had metastatic first-line therapy and endocrine-sensitive disease. Survival outcomes were compared between HER2-negative and HER2-low patient groups. Conclusion: HER2-low status had no statistically significant impact on survival in patients treated with palbociclib or ribociclib plus letrozole.

17 October 2024 in Biomolecules and Biomedicine
Verified
Journal Article
Open access
PDF file
NANargiz Majidova Altuntash
Nargiz Majidova Altuntash
MSMustafa Seyyar
Mustafa Seyyar
DBDemet Işık Bayraktar
Demet Işık Bayraktar
GDGulhan Dinc
Gulhan Dinc
EIElfag İsGandarov
Elfag İsGandarov
MSMurat Sarı
Murat Sarı
Many developing countries lack access to recommended first-line treatments for metastatic renal cell carcinoma (mRCC), such as immune checkpoint inhibitors (ICIs) or ICI-tyrosine kinase inhibitor (TKI) combinations. As a result, predictive markers are necessary to identify patients who may benefit from single-agent TKIs for long-term response. This study aims to identify such parameters. This was a multi-centre, retrospective study of patients with mRCC who were undergoing first-line treatment with sunitinib or pazopanib. Patients who had been diagnosed with mRCC and had not experienced disease progression for 36 months or more were deemed to have achieved a long-term response. Predictive clinical and pathological characteristics of patients who did not experience long-term disease progression were investigated. A total of 320 patients from four hospitals were included in the study. The median age of the patients was 60 years (range 20-89 years). According to the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk classification, 109 patients were classified as having favourable risk and 211 were in the intermediate-poor risk group. The median progression-free survival (PFS) and overall survival (OS) for all patients were 12.5 months and 76.4 months, respectively. In the long-term responder’s group, the median PFS was 78.4 months. Among all patients, prior nephrectomy, the Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) <1, and the absence of brain metastasis were predictive factors for long-term response. For patients in the favourable risk group, the lack of brain metastasis was a predictor of long-term response. In the intermediate-poor risk group, prior nephrectomy and ECOG PS <1 were predictive factors for long-term response. Some individuals with mRCC may experience a durable response to TKIs. The likelihood of a long-term response can be determined by factors such as nephrectomy, ECOG PS < 1, and the absence of brain metastases.

18 September 2026
Verified
Book
Open access
PDF file
AYAlper Yasar
Alper Yasar
Kanser tedavisinde immünoterapi, son yirmi yılda cerrahi, radyoterapi ve kemoterapinin yanına dördüncü bir sütun olarak yerleşmiştir. İmmün kontrol noktası inhibitörlerinin klinik pratiğe girmesinden CAR-T hücre tedavilerinin hematolojik malignitelerde rutin uygulamaya geçmesine kadar geçen süreçte, onkoloji pratiği köklü bir dönüşüm yaşamıştır. Bugün melanomdan akciğer kanserine, renal hücreli karsinomdan Hodgkin lenfomaya kadar pek çok tümör tipinde immünoterapiler standart tedavi algoritmalarının ayrılmaz bir parçası haline gelmiştir. Bu dönüşümün getirdiği en büyük klinik zorluklardan biri, immünoterapilerin geleneksel kemoterapilerden temelde farklı bir toksisite profiline sahip olmasıdır. İmmün sistemin tümöre karşı aktive edilmesi, istenmeyen bir şekilde sağlıklı dokulara karşı da otoimmün benzeri reaksiyonlara yol açabilmekte; bu durum “immün ilişkili yan etkiler” (immune-related adverse events, irAE) olarak adlandırılan, hemen her organ sistemini tutabilen geniş bir klinik tablo yelpazesi doğurmaktadır. Kolitten pnömonite, miyokarditten hipofizite kadar uzanan bu tablo, onkologların yanı sıra dahiliye uzmanlarını, endokrinologları, gastroenterologları, kardiyologları, nörologları, dermatologları ve yoğun bakım hekimlerini de yakından ilgilendirmektedir. Bu kitap, immünoterapi alan hastaların karşılaşabileceği yan etkileri sistematik bir şekilde ele almak; bu yan etkilerin patofizyolojisini, klinik sunumunu, tanısal yaklaşımını ve kanıta dayalı yönetim algoritmalarını sağlık profesyonellerine aktarmak amacıyla hazırlanmıştır. Kontrol noktası inhibitörlerinin yanı sıra CAR-T hücre tedavileri, bispesifik antikorlar, antikor-ilaç konjugatları ve sitokin tedavileri gibi diğer immünoterapi modalitelerine özgü toksisiteler de kapsamlı biçimde işlenmiştir. Kitabın her bölümü, güncel uluslararası kılavuzlar (ASCO, ESMO, SITC, NCCN) ve CTCAE (Common Terminology Criteria for Adverse Events) evrelendirme sistemi temel alınarak hazırlanmış; klinik pratikte doğrudan uygulanabilecek algoritmalar, tablolar ve karar şemalarıyla desteklenmiştir. Amacımız, bu hızla gelişen alanda güncel ve pratik bir başucu kaynağı sunmaktır. Bu eserin, immünoterapi alan hastaların güvenli ve etkin yönetiminde görev alan tüm sağlık profesyonellerine faydalı olmasını dileriz.

22 May 2026 in Medicina
Verified
Journal Article
Open access
PDF file
AYAlper Yasar
Alper Yasar
ZYZeynep Yüksel Yaşar
Zeynep Yüksel Yaşar
SYSEDAT YILDIRIM
SEDAT YILDIRIM
ADAkif Doğan
Akif Doğan
TKTugba Kaya
Tugba Kaya
NTNedim Turan
Nedim Turan
Background and Objectives: Positron emission tomography with 18F-FDG (PET-CT) provides a quantitative measure of tumor metabolic activity through the maximum standardized uptake value (SUVmax) of lung tumors—a measure of metabolic activity that may have prognostic value in non-small cell lung cancer (NSCLC). This study evaluated whether preoperative tumor SUVmax predicts outcomes in resected NSCLC. Materials and Methods: This single-center retrospective study included 209 consecutive patients with resected NSCLC who had preoperative FDG PET-CT. SUVmax of the primary tumor was recorded, and patients were stratified into low- and high-SUVmax groups to evaluate survival outcomes. Results: Median age was 62 years and 77% were male. Histologic subtypes were adenocarcinoma (44%), squamous carcinoma (43%), and others (13%), with stage I–III distribution of 39.7%, 33.5%, and 26.8%, respectively. SUVmax demonstrated moderate discrimination for mortality (AUC = 0.652), with an optimal cutoff of 11.14. Patients with SUVmax ≥ 11.14 had significantly worse OS and DFS. However, on multivariate analysis, SUVmax was not an independent predictor of outcomes, while extracapsular invasion (OS) and adjuvant chemotherapy (DFS) remained significant. Conclusions: In this cohort of resected NSCLC, high preoperative SUVmax (≥11.14) was associated with more advanced tumor stage and worse OS/DFS but was not an independent prognostic factor after accounting for other variables. Tumor invasiveness and use of adjuvant therapy were stronger outcome predictors. Preoperative SUVmax may help identify high-risk patients when considered alongside established clinicopathologic factors.